Hemato Oncology Testing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Hemato Oncology Testing Market is segmented by Product & Services (Assay Kits and Reagents and Services), Cancer Type (Leukemia, Lymphoma, Multiple Myeloma, and Others), Technology (Polymerase chain reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Other Technology), End-User (Hospitals, Academic & Research Institutes, and Other End-Users) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).

Hemato Oncology Testing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Hemato Oncology Testing Market Size

Hemato Oncology Testing Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 5.00 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Hemato Oncology Testing Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Hemato Oncology Testing Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Hemato Oncology Testing Market Analysis

The Global Hemato Oncology Testing Market is expected to register a CAGR of 5% during the forecast period.

The COVID-19 outbreak significantly impacted the availability of hospital resources for cancer care worldwide. For instance, according to an article published by Hematological Oncology in October 2022, the COVID-19 pandemic introduced significant changes in oncologic practice globally, including lymphoma care with a substantial burden on patients and healthcare providers and the potential worsening of patient outcomes. Moreover, according to an article published by the Journal of Clinical Oncology in September 2022, a study was conducted in the United States, which showed that the number of newly diagnosed multiple myeloma patients decreased by 22% during the initial pandemic. However, in the later phase of the pandemic, there was an increase in the demand for cancer diagnostics, including hematological cancers. Thus, the market witnessed significant challenges during the initial phase of the pandemic, but as the SARS-CoV-2 cases started to decline, cancer care went back to normal, and the market witnessed significant growth over time.

The factors that are driving the market growth are the increasing incidence of hematologic cancer and the growing demand for personalized therapy. According to an article updated by PubMed Central in April 2022, leukemia is considered one of the most common cancers in children younger than five years of age, and it accounts for a high percentage of deaths, creating a significant burden on individuals, families, and countries. The occurrence of leukemia in children is leading to the increase in demand for hemato oncology testing, thereby driving the demand for products and services associated with it.

Besides, the growing demand for personalized therapy is also significantly contributing to the market growth. Personalized medicine aims to provide tailor-made therapies to individual patients depending on the molecular basis of the disease, and it has become popular over recent years. The rise in the prevalence of various types of cancer, affordability of personalized medicine therapy in cancer drugs and various other disease indications, fewer side-effects of personalized medicine, and high adoption in developed markets are factors that are creating demand for personalized therapy. Moreover, various firms are conduction studies to prove the effectiveness of personalized medicine in blood-related cancer. For instance, in September 2021, the UC Cancer Center researchers joined a national collaborative, personalized medicine clinical trial for developing personalized treatments for blood and bone cancer.

Additionally, the launch of products is also propelling the market's growth. For instance, in May 2022, Genes2Me launched next-generation sequencing (NGS) based clinical panels for oncology, personalized medicine, and hereditary diseases in India. Furthermore, in October 2021, Sysmex Inostics developed a new liquid biopsy test for the detection of minimal residual disease (MRD) in acute myeloid leukemia (AML). The new test, AML-MRD-SEQ, uses a targeted next-generation sequencing (NGS) panel that covers 68 regions across 20 genes, including established MRD markers such as NPM1.

However, unfavorable reimbursement scenarios may slow down the growth of the studied market.

Hemato Oncology Testing Industry Overview

The hemato-oncology testing market is fragmented and competitive in nature. The companies have been following various strategies such as acquisitions, partnerships, investments in research activities, and new product launches to sustain themselves among the competitors in the global market. The market consists of several major players, and a few of the major players are currently dominating the market, which include F. Hoffmann-La Roche Ltd, Abbott, QIAGEN, Thermo Fisher Scientific Inc., and Illumina Inc.

Hemato Oncology Testing Market Leaders

  1. Abbott

  2. QIAGEN

  3. F. Hoffmann-La Roche Ltd

  4. Illumina Inc.

  5. Thermo Fisher Scientific Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Picture4.png
Need More Details on Market Players and Competiters?
Download PDF

Hemato Oncology Testing Market News

  • December 2022: Alercell announced they are all set to launch LENA Q51(R) in January 2023. It is a leukemia diagnostic test based on sequencing DNA that will detect up to 51 Genes mutations in leukemia patients.
  • June 2022: Burning Rock Biotech Limited received a CE marking for its OverC multi-cancer detection blood test. OverC Multi-Cancer Detection Blood Test is a qualitative next-generation sequencing (NGS)-based in vitro diagnostic device.

Hemato Oncology Testing Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Hematologic Cancer
    • 4.2.2 Growing Demand for Personalized Therapy
  • 4.3 Market Restraints
    • 4.3.1 Unfavorable Reimbursement Scenario
  • 4.4 Porter Five Forces
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product & Services
    • 5.1.1 Assay Kits and Reagents
    • 5.1.2 Services
  • 5.2 By Cancer Type
    • 5.2.1 Leukemia
    • 5.2.2 Lymphoma
    • 5.2.3 Multiple Myeloma
    • 5.2.4 Others
  • 5.3 By Technology
    • 5.3.1 Polymerase chain reaction (PCR)
    • 5.3.2 Immunohistochemistry (IHC)
    • 5.3.3 Next-Generation Sequencing (NGS)
    • 5.3.4 Other Technology
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Academic & Research Institutes
    • 5.4.3 Other End-Users
  • 5.5 Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 F. Hoffmann-La Roche Ltd
    • 6.1.2 Abbott
    • 6.1.3 Invitae Corporation (Archerdx, Inc)
    • 6.1.4 QIAGEN
    • 6.1.5 Thermo Fisher Scientific Inc.
    • 6.1.6 Illumina Inc.
    • 6.1.7 Bio-Rad Laboratories, Inc.-
    • 6.1.8 Molecularmd (Subsidiary of Icon PLC)
    • 6.1.9 Asuragen, Inc.
    • 6.1.10 Arup Laboratories Inc.
    • 6.1.11 Icon PLC
    • 6.1.12 Adaptive Biotechnologies.
    • 6.1.13 Invivoscribe, Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Hemato Oncology Testing Industry Segmentation

As per the scope of the report, hemato-oncology refers to the science which is associated with the diagnosis, treatment, and prevention of blood-related diseases and cancer. The Hemato Oncology Testing Market is segmented by Product & Services (Assay Kits and Reagents, Services), Cancer Type (Leukemia, Lymphoma, Multiple Myeloma, and Others), Technology (Polymerase chain reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Other Technology), End-User (Hospitals, Academic & Research Institutes, and Other End-Users) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product & Services Assay Kits and Reagents
Services
By Cancer Type Leukemia
Lymphoma
Multiple Myeloma
Others
By Technology Polymerase chain reaction (PCR)
Immunohistochemistry (IHC)
Next-Generation Sequencing (NGS)
Other Technology
By End User Hospitals
Academic & Research Institutes
Other End-Users
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Hemato Oncology Testing Market Research FAQs

What is the current Global Hemato Oncology Testing Market size?

The Global Hemato Oncology Testing Market is projected to register a CAGR of 5% during the forecast period (2025-2030)

Who are the key players in Global Hemato Oncology Testing Market?

Abbott, QIAGEN, F. Hoffmann-La Roche Ltd, Illumina Inc. and Thermo Fisher Scientific Inc. are the major companies operating in the Global Hemato Oncology Testing Market.

Which is the fastest growing region in Global Hemato Oncology Testing Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Hemato Oncology Testing Market?

In 2025, the North America accounts for the largest market share in Global Hemato Oncology Testing Market.

What years does this Global Hemato Oncology Testing Market cover?

The report covers the Global Hemato Oncology Testing Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Hemato Oncology Testing Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Hemato Oncology Testing Industry Report

Statistics for the 2025 Global Hemato Oncology Testing market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Hemato Oncology Testing analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Hemato Oncology Testing Market Report Snapshots